Terug
Dagbereik
€ 86,16
€ 87,30
52-Weeksbereik
€ 79,55
€ 106,33
Volume
5.008.889
50D / 200D Gem.
€ 96,83
/
€ 94,49
Vorige Slotkoers
€ 87,17
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 23,8 | 0,3 |
| P/B | 2,3 | 2,9 |
| ROE % | 9,5 | 3,7 |
| Net Margin % | 13,9 | 3,8 |
| Rev Growth 5Y % | 2,7 | 10,0 |
| D/E | 0,6 | 0,2 |
Koersdoel Analisten
Hold
€ 111,45
+28.7%
Low: € 100,00
High: € 120,00
Forward K/W
15,4
Forward WPA
€ 5,65
WPA Groei (sch.)
+0,0%
Omzet Sch.
36 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 7,77
€ 7,55 – € 7,88
|
46 B | 3 |
| FY2029 |
€ 7,14
€ 6,94 – € 7,25
|
43 B | 3 |
| FY2028 |
€ 6,54
€ 5,85 – € 7,17
|
41 B | 9 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 15, 2025 |
Marinaro Michael
EVP, Pres MedSurg and Americas
|
other | 1.371 | € 99,87 | € 136.922 |
| Dec 15, 2025 |
Wall Brett A.
EVP & Pres Neuroscience
|
other | 439 | € 99,87 | € 43.843 |
| Dec 15, 2025 |
Martha Geoffrey
Chairman and CEO
|
other | 1.564 | € 99,87 | € 156.197 |
| Dec 5, 2025 |
KIIL HARRY SKIP
EVP & President Cardiovascular
|
other | 1.702 | € 101,36 | € 172.515 |
| Nov 20, 2025 |
Blomquist Denise L.
Chief Accounting Officer
|
other | 170 | — | — |
| Nov 19, 2025 |
Smith Gregory L
EVP Global Ops & Supply Chain
|
sell | 30.000 | € 101,93 | € 3.058.451 |
| Aug 25, 2025 |
Jellison William R
Director
|
buy | 2.500 | € 92,37 | € 230.925 |
| Aug 22, 2025 |
Jellison William R
Director
|
buy | 2.500 | € 92,73 | € 231.825 |
| Aug 20, 2025 |
Marinaro Michael
EVP, Pres MedSurg and Americas
|
other | 1.052 | € 93,22 | € 98.067 |
| Jul 31, 2025 |
Smith Gregory L
EVP Global Ops & Supply Chain
|
other | 1.630 | € 90,24 | € 147.091 |
| Jun 3, 2025 |
Blomquist Denise L.
Chief Accounting Officer
|
other | 310 | — | — |
| Apr 29, 2025 |
Lofton Kevin E
Director
|
other | 216 | € 84,60 | € 18.274 |
| Apr 29, 2025 |
Fonseca Lidia
Director
|
other | 216 | € 84,60 | € 18.274 |
| Apr 29, 2025 |
Powell Kendall J
Director
|
other | 216 | € 84,60 | € 18.274 |
| Apr 29, 2025 |
HOGAN RANDALL J
Director
|
other | 216 | € 84,60 | € 18.274 |
| Apr 29, 2025 |
DONNELLY SCOTT C
Director
|
other | 216 | € 84,60 | € 18.274 |
| Apr 28, 2025 |
Lofton Kevin E
Director
|
grant | 2.083 | € 84,04 | € 175.055 |
| Apr 28, 2025 |
Fonseca Lidia
Director
|
grant | 2.083 | € 84,04 | € 175.055 |
| Apr 28, 2025 |
Powell Kendall J
Director
|
grant | 2.083 | € 84,04 | € 175.055 |
| Apr 28, 2025 |
HOGAN RANDALL J
Director
|
grant | 2.083 | € 84,04 | € 175.055 |
Belangrijkste Punten
Revenue grew 2,73% annually over 5 years — modest growth
Earnings grew 26,82% over the past year
Generating 5,19B in free cash flow
PEG of 0,75 suggests growth is underpriced
Cash machine — converts 111,22% of earnings into free cash flow
Capital efficient — spends only 5,54% of revenue on capex
Groei
Revenue Growth (5Y)
2,73%
Revenue (1Y)3,62%
Earnings (1Y)26,82%
FCF Growth (3Y)6,40%
Kwaliteit
Return on Equity
9,49%
ROIC5,84%
Net Margin13,90%
Op. Margin17,76%
Veiligheid
Debt / Equity
0,59
Current Ratio1,85
Interest Coverage8,17
Waardering
P/E Ratio
23,84
P/B Ratio2,31
EV/EBITDA23,08
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 3,62% | Revenue Growth (3Y) | 3,63% |
| Earnings Growth (1Y) | 26,82% | Earnings Growth (3Y) | 11,38% |
| Revenue Growth (5Y) | 2,73% | Earnings Growth (5Y) | 6,63% |
| Profitability | |||
| Revenue (TTM) | 33,54B | Net Income (TTM) | 4,66B |
| ROE | 9,49% | ROA | 5,09% |
| Gross Margin | 65,32% | Operating Margin | 17,76% |
| Net Margin | 13,90% | Free Cash Flow (TTM) | 5,19B |
| ROIC | 5,84% | FCF Growth (3Y) | 6,40% |
| Safety | |||
| Debt / Equity | 0,59 | Current Ratio | 1,85 |
| Interest Coverage | 8,17 | Dividend Yield | 0,03% |
| Valuation | |||
| P/E Ratio | 23,84 | P/B Ratio | 2,31 |
| P/S Ratio | 3,31 | PEG Ratio | 0,75 |
| EV/EBITDA | 23,08 | Dividend Yield | 0,03% |
| Market Cap | 111,16B | Enterprise Value | 137,46B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 33,54B | 32,36B | 31,23B | 31,69B | 30,12B |
| Net Income | 4,66B | 3,68B | 3,76B | 5,04B | 3,61B |
| EPS (Diluted) | 3,61 | 2,76 | 2,82 | 3,73 | 2,66 |
| Gross Profit | 21,91B | 21,15B | 20,51B | 21,54B | 19,63B |
| Operating Income | 5,96B | 5,14B | 5,49B | 5,75B | 4,48B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 91,68B | 89,98B | 90,95B | 90,98B | 93,08B |
| Total Liabilities | 43,42B | 39,56B | 39,28B | 38,26B | 41,48B |
| Shareholders' Equity | 48,02B | 50,21B | 51,48B | 52,55B | 51,43B |
| Total Debt | 28,52B | 25,02B | 24,36B | 24,11B | 26,39B |
| Cash & Equivalents | 2,22B | 1,28B | 1,54B | 3,71B | 3,59B |
| Current Assets | 23,81B | 21,94B | 21,68B | 23,06B | 22,55B |
| Current Liabilities | 12,88B | 10,79B | 9,05B | 12,39B | 8,51B |